LEXINGTON, Mass.--(EON: Enhanced Online News)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued two patents adding depth and breadth to the protection of the Company’s T2MR® platform and the T2Dx® detection system. Both patents are part of the growing intellectual property estate protecting T2 Bio’s breakthrough detection capabilities, including the Company’s flagship T2Candida® multiplex test panel that detects the presence of species-specific Candida directly from whole blood in approximately three hours without the requirement for blood culturing.
“The issuance of these two new patents highlights T2 Biosystems’ breakthrough diagnostic detection technology, which enables detection of target analytes directly from whole blood samples or other sample types. T2MR provides rapid and accurate results and, in the case of infectious diseases, assists physicians in directing the prompt administration of appropriate therapeutic intervention,” said John McDonough, President and CEO, T2 Biosystems. “The potential of this innovative technology is exemplified by our flagship product, T2Candida, which we expect to launch in 2014. T2Candida should reduce the time to identification of Candida species to approximately three hours from the current blood culture standard of two to five days. Further, these patents provide protection as we develop additional diagnostic tests across the categories of molecular, immunodiagnostic and hemostasis targets.”
The patents describe a sample containing nanoparticles for use in detecting analytes in whole blood samples and the inlet module of the insertable cartridge for use with the T2Dx instrument. US Patent 8,563,298 describes the composition of an analyte and magnetic nanoparticles with specific size and relaxation properties and the ability to specifically bind to an analyte. This patented composition is core and unique to the T2Dx platform assays that use T2MR, a proprietary magnetic resonance detection system, and the claims are protective of the T2Candida assay as well as future assays. Patent USD691,733, “Modular cartridge assembly”, is a follow-on design patent to a previously issued patent protecting the features of the insertable cartridge to dispense a blood sample for use in the T2Candida or other whole blood assay on the T2Dx instrument.
T2 Biosystems patent portfolio consists of 29 issues patents worldwide.
About T2 Biosystems
T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR®, the Company’s proprietary magnetic resonance detector. The T2MR technology has the potential to provide healthcare professionals sensitive, accurate and rapid assay results. The Company’s products detect molecular, hemostasis or immunoassay targets directly from unpurified clinical samples in hospitals, labs and physicians’ offices. For more information, please visit www.t2biosystems.com.